A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease
about
Ivacaftor for patients with cystic fibrosisSignature motifs identify an Acinetobacter Cif virulence factor with epoxide hydrolase activityEpithelial Anion Transport as Modulator of Chemokine SignalingPollutional haze and COPD: etiology, epidemiology, pathogenesis, pathology, biological markers and therapyMucociliary dysfunction in HIV and smoked substance abuseAirway hydration and COPDWill chronic e-cigarette use cause lung disease?Permeation of Therapeutic Drugs in Different Formulations across the Airway Epithelium In VitroModeling and Simulation of Mucus Flow in Human Bronchial Epithelial Cell Cultures - Part I: Idealized Axisymmetric Swirling FlowIncreasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule TherapeuticsMalfolded protein structure and proteostasis in lung diseases.Acquired defects in CFTR-dependent β-adrenergic sweat secretion in chronic obstructive pulmonary disease.Little Cigars are More Toxic than Cigarettes and Uniquely Change the Airway Gene and Protein Expression.Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotypeToll-Like Receptor 4 Engagement Mediates Prolyl Endopeptidase Release from Airway Epithelia via ExosomesSerum- and glucocorticoid-induced protein kinase 1 (SGK1) increases the cystic fibrosis transmembrane conductance regulator (CFTR) in airway epithelial cells by phosphorylating Shank2E protein.Pulmonary matrix metalloproteinase-9 activity in mechanically ventilated children with respiratory syncytial virus.Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftorCystic fibrosis transmembrane conductance regulator activation by roflumilast contributes to therapeutic benefit in chronic bronchitis.Accumulation of metals in GOLD4 COPD lungs is associated with decreased CFTR levels.An autoregulatory mechanism governing mucociliary transport is sensitive to mucus loadCFTR regulates early pathogenesis of chronic obstructive lung disease in βENaC-overexpressing miceA functional anatomic defect of the cystic fibrosis airway.CFTR and lung homeostasis.Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.Interaction non grata between CFTR's correctors and potentiatorsResveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-Induced model of acquired CFTR deficiencyAirway Surface Dehydration Aggravates Cigarette Smoke-Induced Hallmarks of COPD in Mice.Heme oxygenase-1-mediated autophagy protects against pulmonary endothelial cell death and development of emphysema in cadmium-treated miceChannel Gating Regulation by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) First Cytosolic Loop.Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis and Other Diseases of Mucus ClearanceNonantibiotic macrolides prevent human neutrophil elastase-induced mucus stasis and airway surface liquid volume depletion.Pilot evaluation of ivacaftor for chronic bronchitis.Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD.Barrier function of airway tract epitheliumCigarette smoke and CFTR: implications in the pathogenesis of COPDTherapeutic Approaches to Acquired Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction in Chronic Bronchitis.Hydrator Therapies for Chronic Bronchitis. Lessons from Cystic FibrosisInsulin secretion improves in cystic fibrosis following ivacaftor correction of CFTR: a small pilot studyRepair and Remodeling of airway epithelium after injury in Chronic Obstructive Pulmonary Disease
P2860
Q22305938-3E1105FA-E3E3-4F37-A069-8EF570ACA2FFQ24568297-0C0942B9-18D6-4812-9D29-B1394A15F596Q26744381-30436BE3-B863-48BE-B338-99F5545CCDDFQ26767397-D6B51EAF-6997-490C-B0A1-AD7684AEB5BDQ26777222-F29AFD06-E9F4-40A1-B3C3-CA3E9EE5882FQ28082617-CA0214E8-B4A6-4005-BFB7-7A451D86A0EFQ28267832-D0734463-4B3D-40C0-B09D-A8AA7B4AA965Q28547301-8BDAC793-62BE-4D29-B8FA-8BFCEBF6ED52Q28553402-2F134107-B46E-4F47-B2E3-EB16A8C8F60BQ28554668-2309777E-4BB5-4E60-A85D-9E957B581DFDQ30353585-F9DE83D6-1408-44BB-8B73-086B456E95FEQ33586131-103D7E65-BE1C-4012-B9C9-9CA239F255F0Q33608429-4779361B-AE36-46DD-8910-4A489052936AQ33633486-AA1B3F33-A1B6-458B-8F3C-CA2CA56DC85FQ33756865-ED0313A3-A0A7-4608-8FB7-83E8DAE2A1A0Q33761328-DC2296A9-CBA1-40C3-8FD8-89618EE6D6B4Q33762362-FE639AFE-0421-478C-ABB7-F17A9EE26FE3Q33799590-5D4FD167-59D4-43D0-BE74-1153C9AC78E4Q33799668-A54B525C-6962-4F66-8D67-078CA20011EAQ33930707-1369586B-DA93-4F49-9629-CD64591B609DQ34305540-17AEAF21-AD82-4DA5-888A-167CEE6B822CQ34399667-D8708209-0636-4376-BF4D-AF6B9E290056Q34425996-A181EB7A-AD55-4C43-B74C-E3465C744FCEQ34726856-70D2D5F1-DD40-467F-B84F-477785CA05C3Q34748891-1041002F-6709-45AC-9DBE-F776BBE50298Q35561343-1AB58333-2250-4B24-B1B3-EF38E9385824Q35623246-EFECB165-8BAE-4EF4-814F-01578D8E0A33Q35661242-EF82FEDF-D7D3-4D31-B40B-457B89D04216Q35916871-10867742-B3FA-404C-AC1A-9C8BE39E0F3FQ36489303-BF41E0DA-ABC4-42EE-90B9-4654D73C7598Q36567237-45328B8F-ED3A-4892-88E9-6C616C2941C3Q36923902-2BDCB4A4-870E-4632-B85F-3A42B5E19941Q37028545-D13676AF-FC48-48AB-ADC1-4B515028B4FCQ37073820-74064180-FF78-406F-9B42-B1EF492BE145Q37197947-59595925-5F63-4560-981B-11E18300105DQ37234904-B93B54EE-D79E-44D1-AE86-B88FCD55921CQ37241561-8DE405ED-F497-4397-95D6-48800AF521D2Q37241563-F01E3CAA-2430-414F-8250-B7170F1893EEQ37246186-622433E8-7361-4442-B828-15B8AF03A044Q37265236-882389B7-8BF4-497D-850F-918A3BAA8987
P2860
A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A pharmacologic approach to ac ...... n smoking related lung disease
@ast
A pharmacologic approach to ac ...... n smoking related lung disease
@en
A pharmacologic approach to ac ...... n smoking related lung disease
@nl
type
label
A pharmacologic approach to ac ...... n smoking related lung disease
@ast
A pharmacologic approach to ac ...... n smoking related lung disease
@en
A pharmacologic approach to ac ...... n smoking related lung disease
@nl
prefLabel
A pharmacologic approach to ac ...... n smoking related lung disease
@ast
A pharmacologic approach to ac ...... n smoking related lung disease
@en
A pharmacologic approach to ac ...... n smoking related lung disease
@nl
P2093
P2860
P921
P3181
P1433
P1476
A pharmacologic approach to ac ...... n smoking related lung disease
@en
P2093
Andrew Wilhelm
Clifford Courville
Elina Levin
Eric J Sorscher
Kyle Backer
Li Ping Tang
Marina Mazur
Mark T Dransfield
Peter A Sloane
S Vamsee Raju
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0039809
P407
P577
2012-01-01T00:00:00Z